Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christian Wessling

Family Medicine Saint Louis, MO Medical Doctor

NPI 1174611255 CMS profile 53481

7979 Big Bend Blvd, Saint Louis, MO 63119

Open in the dashboard

General payments

$187

2 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christian Wessling of Saint Louis, MO is reported in the CMS Open Payments database as having received $187 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75 1
2021 General $112 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christian Wessling
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Christian Wessling were reported at $75. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Christian Wessling Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $112 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $75 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Aytu BioScience, Inc $112 1 payment
  2. Antares Pharma, Inc. $75 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $187 2 payments
Products named General payments · program years 2021–2025
  1. Natesto $112 1 payment
  2. XYOSTED $75 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

4,145

Median for Family Practice: 1,826

Drug cost

$195,898

Median for Family Practice: $120,094

Branded share of claims

23%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 46 $49,329
Ozempic Semaglutide Brand 24 $28,281
Eliquis Apixaban Brand 30 $27,692
Synthroid Levothyroxine Sodium Brand 116 $12,274
Armour Thyroid Thyroid,pork Brand 112 $8,917
Synjardy Empagliflozin/Metformin Hcl Brand 11 $6,605
Estradiol (Twice Weekly) Estradiol Brand 63 $6,052
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 18 $5,301
Liothyronine Sodium Generic 111 $4,928
Np Thyroid Thyroid,pork Brand 62 $4,854

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$108,075

Medicare's payments for the services billed

Medicare patients

469

Average age 73

Services billed

1,834

340 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 46%
Arthritis 43%
Osteoporosis 21%
Ischemic heart disease 18%
Depression 16%
Cancer 14%
Atrial fibrillation 13%
Diabetes 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record